vs
ProFrac Holding Corp.（ACDC）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
ProFrac Holding Corp.的季度营收约是Orthofix Medical Inc.的2.0倍（$436.5M vs $219.9M），Orthofix Medical Inc.净利率更高（-1.0% vs -33.2%，领先32.1%），Orthofix Medical Inc.同比增速更快（2.0% vs -4.0%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $12.9M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs -13.4%）
ProFrac Holding Corp.是一家领先的北美能源服务企业，主要为油气勘探开采企业提供水力压裂、完井及相关配套服务，核心客户覆盖美国、加拿大主要陆上页岩及常规油气产区的上游运营商。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
ACDC vs OFIX — 直观对比
营收规模更大
ACDC
是对方的2.0倍
$219.9M
营收增速更快
OFIX
高出6.0%
-4.0%
净利率更高
OFIX
高出32.1%
-33.2%
自由现金流更多
OFIX
多$3.9M
$12.9M
两年增速更快
OFIX
近两年复合增速
-13.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $436.5M | $219.9M |
| 净利润 | $-144.7M | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | -24.9% | 0.2% |
| 净利率 | -33.2% | -1.0% |
| 营收同比 | -4.0% | 2.0% |
| 净利润同比 | -37.8% | 92.4% |
| 每股收益（稀释后） | $-0.83 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACDCOFIX
| Q4 25 | $436.5M | $219.9M | ||
| Q3 25 | $403.1M | $205.6M | ||
| Q2 25 | $501.9M | $203.1M | ||
| Q1 25 | $600.3M | $193.6M | ||
| Q4 24 | $454.7M | $215.7M | ||
| Q3 24 | $575.3M | $196.6M | ||
| Q2 24 | $579.4M | $198.6M | ||
| Q1 24 | $581.5M | $188.6M |
净利润ACDCOFIX
| Q4 25 | $-144.7M | $-2.2M | ||
| Q3 25 | $-100.9M | $-22.8M | ||
| Q2 25 | $-105.9M | $-14.1M | ||
| Q1 25 | $-17.5M | $-53.1M | ||
| Q4 24 | $-105.0M | $-29.1M | ||
| Q3 24 | $-45.2M | $-27.4M | ||
| Q2 24 | $-66.7M | $-33.4M | ||
| Q1 24 | $1.8M | $-36.0M |
毛利率ACDCOFIX
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% | ||
| Q1 24 | — | 67.5% |
营业利润率ACDCOFIX
| Q4 25 | -24.9% | 0.2% | ||
| Q3 25 | -19.5% | -8.3% | ||
| Q2 25 | -10.8% | -7.9% | ||
| Q1 25 | 2.7% | -25.2% | ||
| Q4 24 | -10.3% | -5.3% | ||
| Q3 24 | -0.7% | -9.6% | ||
| Q2 24 | -8.5% | -12.5% | ||
| Q1 24 | 6.9% | -15.6% |
净利率ACDCOFIX
| Q4 25 | -33.2% | -1.0% | ||
| Q3 25 | -25.0% | -11.1% | ||
| Q2 25 | -21.1% | -6.9% | ||
| Q1 25 | -2.9% | -27.4% | ||
| Q4 24 | -23.1% | -13.5% | ||
| Q3 24 | -7.9% | -13.9% | ||
| Q2 24 | -11.5% | -16.8% | ||
| Q1 24 | 0.3% | -19.1% |
每股收益（稀释后）ACDCOFIX
| Q4 25 | $-0.83 | $-0.05 | ||
| Q3 25 | $-0.60 | $-0.57 | ||
| Q2 25 | $-0.67 | $-0.36 | ||
| Q1 25 | $-0.12 | $-1.35 | ||
| Q4 24 | $-0.67 | $-0.76 | ||
| Q3 24 | $-0.29 | $-0.71 | ||
| Q2 24 | $-0.42 | $-0.88 | ||
| Q1 24 | $0.00 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $22.9M | $82.0M |
| 总债务越低越好 | $832.7M | — |
| 股东权益账面价值 | $717.5M | $450.0M |
| 总资产 | $2.6B | $850.6M |
| 负债/权益比越低杠杆越低 | 1.16× | — |
8季度趋势，按日历期对齐
现金及短期投资ACDCOFIX
| Q4 25 | $22.9M | $82.0M | ||
| Q3 25 | $58.0M | $62.9M | ||
| Q2 25 | $26.0M | $65.6M | ||
| Q1 25 | $16.0M | $58.0M | ||
| Q4 24 | $14.8M | $83.2M | ||
| Q3 24 | $25.5M | $30.1M | ||
| Q2 24 | $24.0M | $26.4M | ||
| Q1 24 | $28.3M | $27.0M |
总债务ACDCOFIX
| Q4 25 | $832.7M | — | ||
| Q3 25 | $907.0M | $157.2M | ||
| Q2 25 | $941.9M | $157.0M | ||
| Q1 25 | $967.9M | $156.9M | ||
| Q4 24 | $936.1M | $157.0M | ||
| Q3 24 | $986.7M | $118.5M | ||
| Q2 24 | $1.0B | $118.0M | ||
| Q1 24 | $895.1M | $118.2M |
股东权益ACDCOFIX
| Q4 25 | $717.5M | $450.0M | ||
| Q3 25 | $862.0M | $442.5M | ||
| Q2 25 | $875.5M | $458.3M | ||
| Q1 25 | $988.1M | $458.3M | ||
| Q4 24 | $1.0B | $503.1M | ||
| Q3 24 | $1.1B | $525.9M | ||
| Q2 24 | $1.1B | $546.0M | ||
| Q1 24 | $1.2B | $570.3M |
总资产ACDCOFIX
| Q4 25 | $2.6B | $850.6M | ||
| Q3 25 | $2.7B | $832.6M | ||
| Q2 25 | $2.8B | $837.2M | ||
| Q1 25 | $3.0B | $823.1M | ||
| Q4 24 | $3.0B | $893.3M | ||
| Q3 24 | $3.1B | $867.9M | ||
| Q2 24 | $3.2B | $882.0M | ||
| Q1 24 | $3.0B | $906.0M |
负债/权益比ACDCOFIX
| Q4 25 | 1.16× | — | ||
| Q3 25 | 1.05× | 0.36× | ||
| Q2 25 | 1.08× | 0.34× | ||
| Q1 25 | 0.98× | 0.34× | ||
| Q4 24 | 0.93× | 0.31× | ||
| Q3 24 | 0.90× | 0.23× | ||
| Q2 24 | 0.88× | 0.22× | ||
| Q1 24 | 0.74× | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $49.5M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $12.9M | $16.8M |
| 自由现金流率自由现金流/营收 | 3.0% | 7.6% |
| 资本支出强度资本支出/营收 | 8.4% | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $19.6M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流ACDCOFIX
| Q4 25 | $49.5M | $27.7M | ||
| Q3 25 | $900.0K | $12.4M | ||
| Q2 25 | $100.4M | $11.6M | ||
| Q1 25 | $38.7M | $-18.4M | ||
| Q4 24 | $76.5M | $23.7M | ||
| Q3 24 | $98.2M | $11.7M | ||
| Q2 24 | $113.5M | $9.0M | ||
| Q1 24 | $79.1M | $-18.6M |
自由现金流ACDCOFIX
| Q4 25 | $12.9M | $16.8M | ||
| Q3 25 | $-33.4M | $2.5M | ||
| Q2 25 | $53.9M | $4.5M | ||
| Q1 25 | $-13.8M | $-25.1M | ||
| Q4 24 | $13.3M | $15.2M | ||
| Q3 24 | $28.2M | $6.3M | ||
| Q2 24 | $51.6M | $-360.0K | ||
| Q1 24 | $19.2M | $-29.1M |
自由现金流率ACDCOFIX
| Q4 25 | 3.0% | 7.6% | ||
| Q3 25 | -8.3% | 1.2% | ||
| Q2 25 | 10.7% | 2.2% | ||
| Q1 25 | -2.3% | -13.0% | ||
| Q4 24 | 2.9% | 7.0% | ||
| Q3 24 | 4.9% | 3.2% | ||
| Q2 24 | 8.9% | -0.2% | ||
| Q1 24 | 3.3% | -15.4% |
资本支出强度ACDCOFIX
| Q4 25 | 8.4% | 4.9% | ||
| Q3 25 | 8.5% | 4.8% | ||
| Q2 25 | 9.3% | 3.5% | ||
| Q1 25 | 8.7% | 3.5% | ||
| Q4 24 | 13.9% | 4.0% | ||
| Q3 24 | 12.2% | 2.7% | ||
| Q2 24 | 10.7% | 4.7% | ||
| Q1 24 | 10.3% | 5.6% |
现金转化率ACDCOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 43.94× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACDC
| Services | $385.6M | 88% |
| Products | $50.9M | 12% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
